Header Logo

Connection

Doris Benbrook to Xenograft Model Antitumor Assays

This is a "connection" page, showing publications Doris Benbrook has written about Xenograft Model Antitumor Assays.
  1. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. Int J Cancer. 2020 08 15; 147(4):1086-1097.
    View in: PubMed
    Score: 0.160
  2. Development of flexible-heteroarotinoids for kidney cancer. Mol Cancer Ther. 2009 May; 8(5):1227-38.
    View in: PubMed
    Score: 0.076
  3. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs. 2009 Aug; 27(4):304-18.
    View in: PubMed
    Score: 0.073
  4. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Invest New Drugs. 2005 Oct; 23(5):417-28.
    View in: PubMed
    Score: 0.060
  5. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecol Oncol. 2021 01; 160(1):302-311.
    View in: PubMed
    Score: 0.042
  6. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. AAPS J. 2020 02 21; 22(2):51.
    View in: PubMed
    Score: 0.040
  7. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
    View in: PubMed
    Score: 0.035
  8. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res. 2008 Jul 01; 68(13):5335-44.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.